Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsImportance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataOral antihyperglycemic therapy for type 2 diabetes mellitus.Implications of the global increase of diabetes for tuberculosis control and patient care.Tuberculosis and diabetes mellitus: convergence of two epidemics.New onset diabetes after transplantation (NODAT): an overview.The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.Drug-induced endocrine and metabolic disorders.Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.A review of the efficacy and safety of oral antidiabetic drugsPredicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study.Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.Computational models to assign biopharmaceutics drug disposition classification from molecular structure.Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanismCYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm.Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China.Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders.The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.Hit Generation in TB Drug Discovery: From Genome to Granuloma.Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats.Dual effects of rifampin on the pharmacokinetics of atrasentan.The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.
P2860
Q24631021-B3B2D7E9-8ABD-43FF-AABD-2B716B385E1DQ27009128-E2F6140B-9C66-4F97-802F-E46FB9BC31DBQ33713451-1C81ABD2-0B28-4FEB-9B04-B0743D3B2FACQ33721305-D2CECEF8-7620-438B-A008-049B1B8DDA93Q34156234-68BFE59D-B275-4028-ABCF-699104B7A79BQ35092351-E4D3268C-E878-40C7-9D38-D3281C77167BQ35827353-72737F64-2628-4E72-9F13-010C25CF6D7BQ36718446-982D3BF4-79A5-45F9-9F0D-B7EBA32E2743Q36753691-18012024-EC14-43B3-9183-CE97E939E975Q37631831-2AB46720-0272-437E-8008-E743E3299385Q38059889-4961205E-66F1-4E05-B700-AAA559815759Q38067491-0D623260-EB02-45A2-BC04-BB1899A3B49FQ38087695-B862613B-93D9-405E-8B84-5D5CF99AC290Q38284468-D326305A-B0DC-45C1-93CA-3F75F5BA13EAQ38437256-934D2EEC-C9BE-4811-9429-E57B1949A862Q39212609-0282B647-F429-4809-8C6B-13AC1BC4419EQ40175522-D4E0EB73-B054-454F-B983-E5C82A2D85A0Q41589503-70BD836E-4D18-421E-B89F-2A73E982E78BQ41826580-BCC29AFF-AED1-42F6-8B9D-5B41249C6675Q43154040-1518F2FC-E3E4-4906-89BC-DEC44BA0C400Q45934017-82A7D9E2-CF64-4E9C-9E92-6AF4EBE451B3Q46132298-2E2D34F0-6A00-4072-8F6C-E566DF7CD917Q46512137-C3FFB3C8-EC6A-47BD-8C39-31AE42382633Q46664324-0786B252-54BE-4E6A-9292-E89705DA7081Q47702665-0B3BD571-8C93-4013-A314-E8D90AEB32C5Q48096907-743E4728-E9AB-4F3B-8AF7-BA65386C5520Q48473609-D093BAAB-DAF0-4C84-B655-B8CD19740B10Q48809049-B40A0C69-F27A-487C-A578-EC7F2C461630
P2860
Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Influence of drugs interacting ...... glucose regulator repaglinide.
@en
Influence of drugs interacting ...... glucose regulator repaglinide.
@nl
type
label
Influence of drugs interacting ...... glucose regulator repaglinide.
@en
Influence of drugs interacting ...... glucose regulator repaglinide.
@nl
prefLabel
Influence of drugs interacting ...... glucose regulator repaglinide.
@en
Influence of drugs interacting ...... glucose regulator repaglinide.
@nl
P2093
P2860
P356
P1476
Influence of drugs interacting ...... glucose regulator repaglinide.
@en
P2093
Kristian T Hansen
Mikael S Thomsen
Vibeke Hatorp
P2860
P304
P356
10.1177/0091270003253704
P577
2003-06-01T00:00:00Z